Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Kishan J. Pandya; Anuradha R. Thummala; Jennifer J. Griggs; Joseph D. Rosenblatt; Deepak M. Sahasrabudhe; Thomas J. Guttuso; Gary R. Morrow; Joseph A. Roscoe

doi:10.1023/B:BREA.0000010676.54597.22

Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

Kishan J. Pandya, Anuradha R. Thummala, Jennifer J. Griggs, Joseph D. Rosenblatt, Deepak M. Sahasrabudhe, Thomas J. Guttuso, Gary R. Morrow, Joseph A. Roscoe

Medicine

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

Original language	English (US)
Pages (from-to)	87-89
Number of pages	3
Journal	Breast cancer research and treatment
Volume	83
Issue number	1
DOIs	https://doi.org/10.1023/B:BREA.0000010676.54597.22
State	Published - Jan 2004

Keywords

Breast cancer
Gabapentin
Hot flashes
Tamoxifen

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1023/B:BREA.0000010676.54597.22

Fingerprint Dive into the research topics of 'Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer'. Together they form a unique fingerprint.

Cite this

Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. / Pandya, Kishan J.; Thummala, Anuradha R.; Griggs, Jennifer J.; Rosenblatt, Joseph D.; Sahasrabudhe, Deepak M.; Guttuso, Thomas J.; Morrow, Gary R.; Roscoe, Joseph A.

In: Breast cancer research and treatment, Vol. 83, No. 1, 01.2004, p. 87-89.

Research output: Contribution to journal › Article › peer-review

@article{dc54ad1b1b3042a9a14e15a8aea4b525,

title = "Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer",

abstract = "In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.",

keywords = "Breast cancer, Gabapentin, Hot flashes, Tamoxifen",

author = "Pandya, {Kishan J.} and Thummala, {Anuradha R.} and Griggs, {Jennifer J.} and Rosenblatt, {Joseph D.} and Sahasrabudhe, {Deepak M.} and Guttuso, {Thomas J.} and Morrow, {Gary R.} and Roscoe, {Joseph A.}",

year = "2004",

month = jan,

doi = "10.1023/B:BREA.0000010676.54597.22",

language = "English (US)",

volume = "83",

pages = "87--89",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer

AU - Pandya, Kishan J.

AU - Thummala, Anuradha R.

AU - Griggs, Jennifer J.

AU - Rosenblatt, Joseph D.

AU - Sahasrabudhe, Deepak M.

AU - Guttuso, Thomas J.

AU - Morrow, Gary R.

AU - Roscoe, Joseph A.

PY - 2004/1

Y1 - 2004/1

N2 - In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

AB - In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.

KW - Breast cancer

KW - Gabapentin

KW - Hot flashes

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0942301252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942301252&partnerID=8YFLogxK

U2 - 10.1023/B:BREA.0000010676.54597.22

DO - 10.1023/B:BREA.0000010676.54597.22

M3 - Article

C2 - 14997058

AN - SCOPUS:0942301252

VL - 83

SP - 87

EP - 89

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -